BRIEF-Prescient Therapeutics updates on its clinical trials
* updates on its clinical trials with PTX-200 following a serious adverse event in a late-stage patient on its breast cancer trial.
Feb 15 NEL ASA:
* Revenues in Q4 2016 of 50.6 million Norwegian crowns ($6.03 million), compared to 35.6 million crowns in same quarter in 2015
* Q4 EBITDA loss 13.1 million crowns versus loss 1.2 million crowns year ago Source text for Eikon: Further company coverage: ($1 = 8.3926 Norwegian crowns) (Gdynia Newsroom)
* In FY18, company expects strong annual recurring revenue growth in excess of 200 percent